Results 111 to 120 of about 6,967 (165)

Tolvaptan and Autosomal Dominant Polycystic Kidney Disease Progression in Individuals Aged 18-35 Years: A Pooled Database Analysis. [PDF]

Kidney Med
Chebib FT, Dahl N, Zhou X, Garbinsky D, Wang J, Nunna S, Oberdhan D, Fernandes AW.   +7 more
europepmc   +1 more source

PDB105 The Cost-Effectiveness of Dapagliflozin In Combination With Insulin for the Treatment of Type 2 Diabetes Mellitus (T2dm) In Spain [PDF]

Capel, M., Charokopou, M., Schmidt, R., Sánchez-Covisa, J., Verheggen, B.G.   +4 more
core   +1 more source

Liver safety of tolvaptan in patients with autosomal dominant polycystic kidney disease: interim data from a post-authorization safety study. [PDF]

Clin Kidney J
Jaeger T, Lohrmann E, Ezenekwe A, Enekebe K, Kumar R, Nunna S, Fernandes AW, McCormick L, George V.   +8 more
europepmc   +1 more source

Hiponatrémia: diagnóstico e tratamento [PDF]

, 2012
Inês Raposo Vieira da Silva
core  

Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan. [PDF]

Kidney Int Rep
Uchiyama K, Kamano D, Nagasaka T, Hama EY, Shirai R, Sumura R, Kusahana E, Yanai A, Nakayama T, Kimura T, Takahashi R, Kasai T, Tajima T, Hosoya K, Azegami T, Yamaguchi S, Yoshino J, Ito J, Hayashi M, Kanda T, Ishibashi Y, Washida N, Itoh H, Hayashi K.   +23 more
europepmc   +1 more source

Trajectory of Urine Parameters by Adding Herbal Kampo Medicine Goreisan to Tolvaptan in Patients with Congestive Heart Failure. [PDF]

J Clin Med
Kakeshita K, Imamura T, Hida Y, Onoda H, Koike T, Kinugawa K.   +5 more
europepmc   +1 more source

Empagliflozin in patients with autosomal dominant polycystic kidney disease (EMPA-PKD): study protocol for a randomised controlled trial. [PDF]

BMJ Open
Bahlmann-Kroll E, Häckl S, Kramer S, Wulfmeyer VC, Glandorf J, Kaufeld J, Koch A, Hartung D, Schmidt BMW, Schmidt-Ott K, Schmitt R.   +10 more
europepmc   +1 more source

Case report: Persistent syndrome of inappropriate antidiuresis after traumatic brain injury: spontaneous resolution and impact on RAAS and bone metabolism over five years. [PDF]

Front Endocrinol (Lausanne)
Liu Y, Tang J, Zhou M, Huang H, Wang T, Zhang M.   +5 more
europepmc   +1 more source

Prospective Study on Individualized Dose Adjustment of Tolvaptan Based on Urinary Osmolality in Patients With ADPKD. [PDF]

Kidney Int Rep
Geertsema P, Soonawala D, Gansevoort RT, Meijer E.   +3 more
europepmc   +1 more source